Your Daily Sleep Science Briefing

New Oral Medication Shows Promise for Sleep Apnea, While Personalized Napping and Anxiety Links Emerge

• A novel once-nightly oral medication, AD109, has demonstrated significant efficacy in a Phase 3 clinical trial for obstructive sleep apnea (OSA), reducing breathing interruptions by approximately 44%. Presented at the 2026 ATS International Conference, this drug, a combination of aroxybutynin and atomoxetine, works by strengthening airway muscles and could provide a much-needed alternative for patients unable to tolerate CPAP therapy.

  Sciencedaily

• The science of napping is evolving, with new research suggesting that personalized advice, potentially informed by genetic analysis, is crucial, as individuals napping against their genetic predisposition may face an increased risk of obesity. Strategic nap length can also influence performance, with REM sleep linked to improved learning and memory, and deep sleep to recovery from exercise.

  Sciencenews

• Just one night of insufficient sleep can significantly heighten anxiety, with neuroscience research indicating a potential increase of up to 30% in anxiety levels the following day. This effect is attributed to the brain's emotional alarm growing louder while regions responsible for control become less active, underscoring the critical role of deep non-REM slow-wave sleep in emotional regulation.

  Spacedaily